Research Article
IL23R and IL12B SNPs and Haplotypes Strongly Associate with Crohn's Disease Risk in a New Zealand Population
Table 1
Summary of Crohn’s disease and controls and Montreal classification data.
| | Crohn’s disease (%) | Control group (%) |
| Gender | | | Female | 223 (68.4) | 199 (37.3) | Male | 103 (31.6) | 335 (62.7) |
| Age at first diagnosis | | | Below 17 | 30 (10.5) | Not applicable | Between 17 and 40 | 204 (71.6) | Above 40 | 51 (17.9) |
| Crohn’s disease location | | | Colonic | 86 (32.2) | Not applicable | Ileal | 97 (36.3) | Ileocolonic | 84 (31.5) |
| Crohn’s disease behaviour | | | Inflammatory | 152 (57.4) | Not applicable | Penetrating | 32 (12.1) | Stricturing | 81 (30.6) | Ileal/stricturing | 47 (40.2) | Colonic/inflammatory | 70 (59.8) |
| Any other families and relatives with IBD | | | Yes | 88 (28.3) | Not applicable | No | 223 (71.7) |
| Bowel resection | | | Yes | 99 (31.8) | Not applicable | No | 212 (68.2) |
| Smoker at diagnosis/smoker at interview | | | Yes | 112 (46.7) | 118 (29.4) | No | 128 (53.3) | 283 (70.6) |
| Extraintestinal manifestations | | | Yes | 44 (14.2) | Not applicable | No | 267 (85.8) |
|
|